Medical Tourism Could Be India's Most Underrated Dollar-Revenue Business
Foreign patients pay full price, often in advance and in hard currency, and they earn hospitals about 30% more per bed. India still treats medical tourism as a side business.
Summary
- Foreign medical arrivals into India rose from about 1.83 lakh in 2020 to about 6.44 lakh in 2024, and the government projects the market to roughly double from $7.69 billion in 2024 to $16.21 billion by 2030.
- For hospitals the value is in the mix: Max says international patients earn about 30% more per occupied bed, pay upfront and sit outside government schemes.
- The risk is concentration. Three in four patients came from Bangladesh in 2024, and when that corridor shook, visas fell by a fifth. The chains now winning are the ones widening their source markets.
A heart bypass that would cost well over $100,000 in the United States is commonly quoted at $5,000 to $10,000 in a good Indian hospital. A hip replacement is a fraction of the American price too. That gap is decades old. What is newer is how much of the world has started acting on it.
Ministry of Tourism data shows about 1.83 lakh foreign arrivals for medical treatment in 2020, the pandemic low, and about 6.44 lakh in 2024. The government, drawing on market research, values the sector at $7.69 billion in 2024 and projects $16.21 billion by 2030, a compound growth rate of about 13%. That is a projection, not a result, but the direction is not in doubt.
The more useful question for a hospital is not whether the market grows. It is whether India, and any individual hospital, is organised to capture the value. Mostly, not yet.
Why the arithmetic works for patients
Official estimates put Indian procedures at 60% to 80% below the cost in developed countries. The saving does not come from cutting clinical corners at accredited hospitals. It comes from lower operating costs, lower malpractice exposure, the exchange rate, and a deep pool of skilled doctors and nurses who cost far less than their Western peers. Many senior Indian specialists trained or practised in the US, UK or Europe, and around 60 Indian hospitals hold JCI accreditation alongside a large and growing base of NABH-accredited ones.
Cardiac surgery, cancer care, transplants, orthopaedics, robotic surgery and fertility treatment all show the same pattern: a large price gap on high-value, planned procedures where a patient has time to compare.
Why it matters to a hospital P&L
International patients are not just more volume. They are better volume. Max Healthcare's management has said foreign patients generate an average revenue per occupied bed about 30% above its network average, and stay about 1.2 times longer, because they tend to come for complex cases. International revenue grew 25% year on year in Q2 FY26 and made up about 9% of hospital revenue.
The reasons are easy to see. These patients usually pay in full, often in advance, in dollars, dirhams or dinars. They sit outside government insurance schemes and their package rates. For a hospital used to waiting months on scheme receivables, that cash profile is worth as much as the higher tariff. Our note on hospital pricing and payer mix sets out why payer mix moves margin more than list price, and the real economics of running a hospital shows how ARPOB flows to the bottom line.
A foreign patient who pays upfront is worth more to a hospital than the tariff alone suggests.
The concentration problem
India's medical tourism rests on a narrow base. Of the roughly 6.44 lakh foreign medical arrivals in 2024, about 4.82 lakh came from Bangladesh, three in every four. Iraq, Somalia, Oman and Uzbekistan follow a long way behind.
That exposure showed in 2024. Political upheaval in Bangladesh and tighter visa processing cut the number of Indian medical visas issued that year by about 22%. Apollo, whose international mix had been about 30% Bangladeshi in early 2024, saw that share fall to 7% to 8% by Q3 FY26. It still grew international revenue 28% that quarter, because it had pushed into Africa, West Asia and Southeast Asia. International patients now contribute about 6% of its revenue.
That is the lesson in one company. A hospital that relies on one corridor has a revenue stream that depends on the politics of another country. A hospital that builds several has a business.
Why India underperforms its product
India ranked 10th in the 2020-21 Medical Tourism Index, behind destinations such as Singapore and Thailand whose health systems are far smaller. The gap is not in the operating theatre. It is in everything around it.
- The patient journey. A foreign patient needs a visa, an airport pickup, a coordinator who speaks their language, somewhere to stay near the hospital, food they can eat during recovery, and a plan for follow-up once home. Thailand and Singapore have a mature facilitator industry and hospital teams that run all of this. India has it at its top hospitals and patchily elsewhere.
- Geography. The volume sits in Chennai, Hyderabad, Bengaluru, Delhi NCR and Mumbai. Most of India's hospital capacity is invisible to foreign patients.
- Source markets. The base is concentrated in neighbouring and West Asian countries with lower spending power. Patients from the US, UK, Europe and Australia, who save the most, are a small share.
- Country marketing. The Heal in India initiative and e-medical visas for citizens of around 170 countries have removed real barriers. But the national promotion effort is still small compared with what Thailand and Singapore spend to sell themselves.
Where the upside is
Western patients. An American who saves most of the cost of cardiac surgery even after flights and a hotel stay is making a rational choice, and more are making it. The visa friction is largely gone. What remains is trust: knowing which hospital to pick, what accreditation means, and that follow-up care will be there after they fly home.
Africa. Patients from East and West Africa increasingly pick India over Thailand or Turkey on clinical reputation and price, and the Apollo numbers show how fast that market can replace a lost one.
Recovery and wellness. India can pair tertiary surgery with rehabilitation in Kerala, Uttarakhand or Rajasthan at a cost no Western rehab facility can match. A patient recovering from joint replacement who spends two more weeks in a wellness centre is worth more to the whole chain of providers, and few destinations can offer the combination.
What a hospital should do
The usual framing treats this as a national branding problem waiting on government. We think that is only half right. Much of it is within a single hospital's control, and the economics justify the spend.
- Price packages, not line items. Foreign patients buy a fixed, all-in quote before they travel. Build procedure packages with clear inclusions and a policy for complications, and hold to them.
- Staff an international desk properly. Coordinators with the right languages, visa support, and a named person who owns each patient from enquiry to follow-up.
- Diversify on purpose. Track revenue by source country, set a ceiling on any one corridor, and put marketing money into the next two markets before you need them.
- Build the follow-up. Teleconsultations after discharge and links with doctors in the source country are what turn one patient into referrals.
- Collect cleanly. Take deposits upfront, reconcile foreign-currency receipts, and keep international billing separate so its margin is visible. Our revenue cycle management monograph covers the controls.
India has the best product in global medical tourism: world-class surgery at a fraction of Western prices, English-speaking specialists and a wellness tradition no rival can copy. The dollar revenue is there for hospitals that build the systems to collect it. SRF works with promoters on exactly these decisions in hospitals and diagnostics, and for chains adding metro capacity, brownfield expansion is often where international beds get added fastest.
How useful was this article?
One tap. It tells us what to write more of.
About the author
SRF Capital Studio
The next one
Get what we publish next, by email.
Working notes on raising, borrowing, protecting, growing and structuring capital in India. One email a week at most, and you can leave any time.
We use your address only to send this. See our privacy policy.
We store your address to send you these emails and nothing else. See our privacy policy.
Related reading
